News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 3, 2006--ImmunoGen, Inc. (Nasdaq:IMGN) will host a conference call at 4:30 p.m. EDT on Thursday, August 10, 2006, to discuss the Company's financial results for the quarter ended June 30, 2006 -- the fourth quarter of ImmunoGen's 2006 fiscal year. Management also will provide an update on the Company.

The call may be accessed live by dialing 913-981-4900. No passcode is required. Playback of the call will be available from 7:30 p.m. on August 10, 2006, through 11:59 p.m. on August 16, 2006. To listen to the playback, please call 719-457-0820 and provide passcode 8945461.

Additionally, the call can be heard through the Investor Relations section of ImmunoGen's website, http://www.immunogen.com. Please connect to this website at least 10 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Following the live webcast, an archived version of the call will be available at the same location through August 16, 2006.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Four TAP compounds are in clinical testing -- huN901-DM1 and huC242-DM4, which are wholly owned by ImmunoGen, and AVE9633 and trastuzumab-DM1, which are in development by the sanofi-aventis Group and Genentech, respectively. Amgen (formerly Abgenix), Biogen Idec, Biotest AG, Boehringer Ingelheim, Centocor, Genentech, Millennium Pharmaceuticals, Inc., and the sanofi-aventis Group have licensed the right to develop and/or test TAP compounds to specific targets; ImmunoGen also has a broader collaboration with the sanofi-aventis Group.

CONTACT: ImmunoGen, Inc., Cambridge
Carol Hausner, 617-995-2500
info@immunogen.com

SOURCE: ImmunoGen, Inc.